Cargando…

Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels

Sedatives and tranquilizers are important in the control of excited camels during camel transport. This study was conducted to investigate the clinical sedation of camels with acepromazine and its correlation with pharmacokinetics and pharmacodynamics. The sedation score, heart rate, respiration, bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandeel, Mahmoud, Almubarak, Adel I., Hussen, Jamal, El-Deeb, Wael, Venugopala, Katharigatta N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455987/
https://www.ncbi.nlm.nih.gov/pubmed/34568476
http://dx.doi.org/10.3389/fvets.2021.725841
_version_ 1784570780338618368
author Kandeel, Mahmoud
Almubarak, Adel I.
Hussen, Jamal
El-Deeb, Wael
Venugopala, Katharigatta N.
author_facet Kandeel, Mahmoud
Almubarak, Adel I.
Hussen, Jamal
El-Deeb, Wael
Venugopala, Katharigatta N.
author_sort Kandeel, Mahmoud
collection PubMed
description Sedatives and tranquilizers are important in the control of excited camels during camel transport. This study was conducted to investigate the clinical sedation of camels with acepromazine and its correlation with pharmacokinetics and pharmacodynamics. The sedation score, heart rate, respiration, body temperature, and pharmacokinetics were monitored before and after acepromazine injection, and myeloid marker expression was analyzed using membrane immunofluorescence and flow cytometry. The distribution (t1/2α) and elimination (t1/2β) half-lives were 0.1 and 9.4 h, respectively. The volume of distribution at steady state (Vss) was 20.01 L/kg, and the mean residence time (MRT) was 12.25 h. Sedation started rapidly within 10 min followed by persistent low-medium sedation for 2 h with an average sedation score of 1.2 ± 0.61, which might be associated with a slow elimination phase and prolonged MRT. Compared to horses, camels showed a lower clearance rate, higher volume of distribution, and higher elimination half-life. Slight changes in body temperature and heart and respiratory rate, as well as a lower hematocrit and changes in blood cell composition, suggest the careful application of acepromazine in animals with abnormal blood parameters or poor vital conditions.
format Online
Article
Text
id pubmed-8455987
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84559872021-09-23 Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels Kandeel, Mahmoud Almubarak, Adel I. Hussen, Jamal El-Deeb, Wael Venugopala, Katharigatta N. Front Vet Sci Veterinary Science Sedatives and tranquilizers are important in the control of excited camels during camel transport. This study was conducted to investigate the clinical sedation of camels with acepromazine and its correlation with pharmacokinetics and pharmacodynamics. The sedation score, heart rate, respiration, body temperature, and pharmacokinetics were monitored before and after acepromazine injection, and myeloid marker expression was analyzed using membrane immunofluorescence and flow cytometry. The distribution (t1/2α) and elimination (t1/2β) half-lives were 0.1 and 9.4 h, respectively. The volume of distribution at steady state (Vss) was 20.01 L/kg, and the mean residence time (MRT) was 12.25 h. Sedation started rapidly within 10 min followed by persistent low-medium sedation for 2 h with an average sedation score of 1.2 ± 0.61, which might be associated with a slow elimination phase and prolonged MRT. Compared to horses, camels showed a lower clearance rate, higher volume of distribution, and higher elimination half-life. Slight changes in body temperature and heart and respiratory rate, as well as a lower hematocrit and changes in blood cell composition, suggest the careful application of acepromazine in animals with abnormal blood parameters or poor vital conditions. Frontiers Media S.A. 2021-09-08 /pmc/articles/PMC8455987/ /pubmed/34568476 http://dx.doi.org/10.3389/fvets.2021.725841 Text en Copyright © 2021 Kandeel, Almubarak, Hussen, El-Deeb and Venugopala. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Kandeel, Mahmoud
Almubarak, Adel I.
Hussen, Jamal
El-Deeb, Wael
Venugopala, Katharigatta N.
Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels
title Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels
title_full Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels
title_fullStr Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels
title_full_unstemmed Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels
title_short Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels
title_sort pharmacokinetic, clinical, and myeloid marker responses to acepromazine sedation in arabian camels
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455987/
https://www.ncbi.nlm.nih.gov/pubmed/34568476
http://dx.doi.org/10.3389/fvets.2021.725841
work_keys_str_mv AT kandeelmahmoud pharmacokineticclinicalandmyeloidmarkerresponsestoacepromazinesedationinarabiancamels
AT almubarakadeli pharmacokineticclinicalandmyeloidmarkerresponsestoacepromazinesedationinarabiancamels
AT hussenjamal pharmacokineticclinicalandmyeloidmarkerresponsestoacepromazinesedationinarabiancamels
AT eldeebwael pharmacokineticclinicalandmyeloidmarkerresponsestoacepromazinesedationinarabiancamels
AT venugopalakatharigattan pharmacokineticclinicalandmyeloidmarkerresponsestoacepromazinesedationinarabiancamels